Pro Medicus (ASX:PME) share price jumps 7% following broker notes

We scan the reasons for the lift in Pro Medicus shares today…

| More on:
Two doctors give the thumbs up to an x-ray

Image source: Getty Images

The Pro Medicus Ltd (ASX: PME) share price surged higher today.

Today’s gain puts the healthcare imaging provider’s share price within reach of its previous all-time high.

Earlier today, Pro Medicus shares reached an intraday high of $57.57. The company’s shares finished the day at $56.87, up 6.9%.

What’s pushing the Pro Medicus share price upwards?

There were no announcements from the company today. However, a couple of snippets of information might have influenced the share price.

Firstly, a broker note out of Morgans reveals its analysts have downgraded their ‘hold’ rating to ‘reduce’. That may not sound positive for the company at first, but the broker did increase its price target from $41.30 to $49.69.

Morgans’ mixed signals are the result of Pro Medicus’ rapid share price appreciation in the last month. Given the lack of news, the broker thinks the upwards move might stem from short positions being covered ahead of the end of the financial year.

For this reason, Mogans sees current prices as unsustainable in the short term.

Another broker’s take

Bell Potter released its latest research on the medical imaging company yesterday. According to the note, the broker retained a ‘hold’ rating with a 12-month Pro Medicus share price target of $49, previously $43.

Additionally, Bell Potter estimated the company’s market share in radiology image viewing as somewhere between 3% to 5%. Hence, the future potential for further expansion remains vast in their opinion.

Topping the 200

The impressive share price performance extends beyond today, this week, or even month. As we covered in a separate story, Pro Medicus is one of the best performing shares in the S&P/ASX 200 Index (ASX: XJO) so far in 2021.

A wave of optimism has followed the company winning a few big contracts in the first six months of the year. Between these deals, Pro Medicus added $85 million in contracted revenue over the next 7 to 8 years.

Should you invest $1,000 in Pro Medicus right now?

Before you consider Pro Medicus, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Pro Medicus wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Motley Fool contributor Mitchell Lawler owns shares of Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers